



RECEIVED

AUG 06 2001

TECH CENTER 1600/2900

PATENT

Customer No. 22,852

Attorney Docket No. 3495.0187-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
COEN et al.) Group Art Unit: 1646 8/B
Serial No.: 09/501,787) Examiner: Jiang M.Q
Filed: February 11, 2000)
For: HYBRID TETANUS TOXOID)
PROTEINS THAT MIGRATE)
RETROGRADELY AND)
TRANSYNAPTICALLY INTO)
THE CNS)
8/7/01

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

RESPONSE TO RESTRICTION REQUIREMENT

In a restriction requirement dated July 3, 2001, the Examiner required restriction under 35 U.S.C. § 121 between:

Group I - Claims 1-16, and 28-31, in part, drawn to a method for *in vivo* delivery of a composition of DNA or cells containing such to CNS, which reads on gene therapy;

Group II - Claims 1-11, and 31, in part, drawn to a method for *in vivo* delivery of a composition of protein to CNS, which reads on protein therapy; and

Group III - Claims 17-27, in part, drawn to a polypeptide, a polynucleotide encoding such, a vector, and a cell containing the polynucleotide.

Preliminary Amendment

Please amend the claims as follows: